摘要
急性淋巴细胞白血病（ALL）为常见的恶性肿瘤。尽管对ALL的临床诊疗方案已有较大改进，但是仍有部分患者复发或者治疗失败。糖皮质激素为ALL的核心治疗药物，然而对糖皮质激素产生耐药性是ALL临床治疗中的常见难题，亦为导致治疗失败的主要原因。ALL对糖皮质激素耐药机制非常复杂，其受到肿瘤细胞表达相关耐药蛋白及多种相关信号通路调控，主要集中于MAKP、PI3K/AKT/mTOR、JAK/STAT、Wnt/β-catenin等信号通路。笔者拟就近年ALL糖皮质激素耐药相关信号通路的研究进展进行综述。
Acute lymphoblastic leukemia （ALL） is the common malignant tumor. Despite the great improvements in clinical protocols, some patients relapse or suffer from failure of treatment. Glucocorticoid is the core drug in the treatment of ALL. However, the resistance of glucocorticoid in ALL is a common problem in clinical treatment and the main cause of failure of treatment. Mechanism of glucocorticoid resistance is very complex. The expression of drug resistance proteins and the production of drug resistance in tumor cells are regulated by multiple signal transduction pathways, which mainly include MAKP, PI3K/AKT/mTOR, JAK/STAT, Wnt/β-catenin signal transduction pathway. In this paper, the recent progresses of glucocorticoid resistance related signal transduction pathway in ALL was reviewed.
作者
龙思利
刘文君
Long Sili;Liu Wenjun(Department of Pediatric,Laboratory of Pediatric Hematology and Oncology,PI Research Laboratory of Children＇s Hematology and Oncology,Affiliated Hospital of Southwest Medical University,Luzhou 646000,Sichuan Province,China)
出处
《国际输血及血液学杂志》
CAS
2018年第5期441-445,共5页
International Journal of Blood Transfusion and Hematology
基金
四川省基础研究项目（14JC0193）
泸州市科技局项目（2016-S-67）
